Ipsen Wins Arbitration Against Galderma Over Aesthetic Toxin Programs
The French biopharmaceutical group Ipsen has prevailed in the International Chamber of Commerce (ICC) Arbitration Tribunal, which dismissed Galderma's request for termination of an R&D agreement, according to the statement released this Wednesday.
Final Decision in Favor of Ipsen
The ICC Arbitration Tribunal has issued a final decision in favor of Ipsen in the dispute against Galderma. This decision, the company states, confirms Ipsen's full rights over its clinical-phase toxin programs in the aesthetic field. The dispute revolved around Ipsen's termination of a research and development agreement with Galderma. The group notes that this outcome allows it to retain complete control over its developments in this segment. David Loew, CEO of Ipsen, stated that this decision supports the group's stance in neuroscience research and development, adding that the company continues to evaluate all options to maximize the value of its IPN10200 candidate.
IPN10200: A Novel Recombinant Molecule
IPN10200 is the first recombinant molecule developed by Ipsen, designed to combine the active A sequence and the B binding sequence. According to the group, this design aims to enhance receptor affinity and internalization, achieving a longer and clinically significant effect duration. The molecule is currently undergoing four Phase II trials in aesthetic and therapeutic indications. Among these trials is LANTIC, a Phase I/II trial involving 727 patients, assessing the safety and efficacy of IPN10200 in three indications of moderate to severe upper facial wrinkles: glabellar lines, forehead wrinkles, and lateral canthal lines. The LANTIC trial is part of the broader development programs for IPN10200 conducted by Ipsen.
Ipsen: A Global Biopharmaceutical Focus
Ipsen is a global biopharmaceutical group focused on the development of innovative medicines in three therapeutic areas: Oncology, Rare Diseases, and Neuroscience. The group's R&D product portfolio is based on internal and external innovation, as well as nearly 100 years of development experience within global hubs located in the United States, France, and the United Kingdom. Ipsen's teams are present in over 40 countries, and its partnerships enable the delivery of its medications to patients in more than 100 countries. The group is listed in Paris on Euronext under the ticker IPN and in the United States through a Level I American Depositary Receipt program.
